Vyluma’s pipeline of therapies is led by NVK002, an investigational, preservative-free, low-dose atropine eye drop ... in developing products for the ophthalmic and injectable markets.
Ireland: A recent study conducted as part of the Myopia Outcome Study of Atropine in Children (MOSAIC) clinical trial explored the long-term effects of 0.01% atropine eye drops on macular choroidal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback